diphenyl urea

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: diphenyl urea
• 英文别名: 1,1'-Biphenyl;urea
• 化学式: CH₄N₂O*C₁₂H₁₀
• 分子量: 214.267
• InChiKey: NFKJHAPTDLJRDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.38
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  二苯二硫醚 在 苯胺 作用下， 以 甲醇 为溶剂， 以5%的产率得到N-苯基甲酰胺
  参考文献：
  名称：

  Promoted method for producing carbamates

  摘要：

  提供了一种生产碳酸酯的方法，该方法包括将有机一级或二级胺与一氧化碳源、含至少一个羟基的有机化合物以及硫、硒或碲源接触，在反应催化剂的存在下，且在至少选自以下组分的存在下：公式为R1-S-S-R2的硫化物，其中R1和R2选自由以下组分的成员：烷基、芳基、环烷基、烷基芳基、芳烷基、杂环、烯基、炔基、烷酰基、芳酰基、前述组分的卤代衍生物，以及在前述组分之一或多个碳原子被氧原子替换的衍生物。

  公开号：

  US04242520A1

文献信息

• DIPHENYL UREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS
  申请人：Allergan, Inc.

  公开号：US20150080466A1

  公开（公告）日：2015-03-19

  The present invention relates to diphenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2.

  本发明涉及二苯基脲衍生物，制备它们的方法，含有它们的药物组合物以及它们作为药物的用途，作为N-甲酰肽受体2的调节剂。
• [EN] AURORA KINASE INHIBITORS<br/>[FR] INHIBITEURS D'AURORA KINASE
  申请人：UNIV CALIFORNIA

  公开号：WO2014190207A1

  公开（公告）日：2014-11-27

  Disclosed herein inter alia are compositions and methods useful in the treatment of cancer and for modulating the activity of Aurora A kinase and/or a Myc family protein.

  本公开的内容包括用于治疗癌症和调节枢纽A激酶和/或Myc家族蛋白活性的组合物和方法。
• Novel benzotriazoles anti-inflammatory compounds
  申请人：Pfizer Inc.

  公开号：US20030078432A1

  公开（公告）日：2003-04-24

  The present invention relates to novel benzotriazoles of the formula I 1 wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R 2 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; R 3 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; s is an integer from 0-5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及公式I的新型苯并三唑 其中Het是一个可选择取代的含有一个到两个来自氮、硫和氧的杂原子的5元杂环，其中至少一个杂原子必须是氮; R 2 选自由氢、(C 1 -C 6 )烷基或其他适当的取代基组成的群; R 3 选自由氢、(C 1 -C 6 )烷基或其他适当的取代基组成的群; s是0-5之间的整数; 用于它们的制备的中间体，含有它们的药物组合物以及它们的药用。本发明的化合物是MAP激酶，优选p38激酶的有效抑制剂。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病发作中的再灌注或缺血、自身免疫疾病和其他疾病中有用。
• Positively-charged peptide nucleic acid analogs with improved properties
  申请人：——

  公开号：US20040034043A1

  公开（公告）日：2004-02-19

  The present invention relates to novel types of peptide nucleic acids (PNAS) with improved properties. In particular, it relates to positively charged PNA units having an ethylene linker between the backbone and the nucleobase, to oligonucleotide analogs comprising these units, to oligomers comprising these units, and to the use of positively charged PNAs as novel delivery agents with therapeutic and diagnostic applications including for antisense therapy.

  本发明涉及具有改进性能的新型肽核酸（PNA）类型。具体而言，涉及具有乙烯连接剂的带正电荷的PNA单元，该连接剂位于骨架和核碱基之间，以及包含这些单元的寡核苷酸类似物、包含这些单元的寡聚体，以及将带正电荷的PNA用作新型传递剂的用途，包括用于反义疗法的治疗和诊断应用。
• Novel benzimidazole anti-inflammatory compounds
  申请人：Pfizer Inc.

  公开号：US20030092749A1

  公开（公告）日：2003-05-15

  The present invention relates to novel triazolo-pyridines of the formula I 1 wherein Het is an optionally substituted 5 -membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R 2 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; R 3 is selected from the group consisting of hydrogen, (C 1 -C6)alkyl or other suitable substituents; s is an integer from 0-5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及公式I的新型三唑基吡啶 其中Het是一个可选择取代的 含有一个到两个氮、硫和氧杂原子的5元杂环，其中至少一个杂原子必须是氮; R 2 选自由氢、(C 1 -C 6 )烷基或其他适当的取代基组成的群; R 3 选自由氢、(C 1 -C6)烷基或其他适当的取代基组成的群; s是0-5之间的整数; 用于它们的制备的中间体，含有它们的药物组合物以及它们的药用。本发明的化合物是MAP激酶，优选为p38激酶的有效抑制剂。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病发中的再灌注或缺血、自身免疫疾病和其他疾病中有用。